Mitchell Shuster Steiner Sells 30,000 Shares of Veru Inc (NASDAQ:VERU) Stock

Share on StockTwits

Veru Inc (NASDAQ:VERU) CEO Mitchell Shuster Steiner sold 30,000 shares of Veru stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $1.93, for a total value of $57,900.00.

Mitchell Shuster Steiner also recently made the following trade(s):

  • On Wednesday, August 7th, Mitchell Shuster Steiner sold 30,000 shares of Veru stock. The shares were sold at an average price of $2.26, for a total value of $67,800.00.
  • On Wednesday, July 3rd, Mitchell Shuster Steiner sold 20,000 shares of Veru stock. The shares were sold at an average price of $2.25, for a total value of $45,000.00.

Veru stock opened at $1.90 on Thursday. Veru Inc has a 52 week low of $1.18 and a 52 week high of $2.49. The company’s 50 day moving average price is $2.03 and its two-hundred day moving average price is $1.80. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.13. The stock has a market cap of $124.87 million, a P/E ratio of -4.87 and a beta of 0.43.

Veru (NASDAQ:VERU) last posted its earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Veru had a negative net margin of 59.68% and a negative return on equity of 50.14%. The firm had revenue of $9.73 million for the quarter, compared to analysts’ expectations of $8.11 million. On average, equities analysts anticipate that Veru Inc will post -0.18 EPS for the current year.

VERU has been the subject of a number of analyst reports. Zacks Investment Research reiterated a “hold” rating on shares of Veru in a research note on Saturday, September 7th. Cantor Fitzgerald began coverage on shares of Veru in a research report on Monday, July 1st. They set an “overweight” rating and a $6.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $4.50 target price on shares of Veru in a research report on Friday, August 9th. Finally, Brookline Capital Management began coverage on shares of Veru in a research report on Monday, July 29th. They set a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $5.71.

Several institutional investors have recently bought and sold shares of VERU. Geode Capital Management LLC lifted its position in shares of Veru by 115.4% during the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock worth $301,000 after buying an additional 115,506 shares in the last quarter. Wedge Capital Management L L P NC bought a new stake in shares of Veru in the 2nd quarter worth approximately $394,000. Renaissance Technologies LLC raised its holdings in shares of Veru by 183.1% in the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock worth $558,000 after purchasing an additional 169,550 shares during the period. BlackRock Inc. raised its holdings in shares of Veru by 65.4% in the 2nd quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock worth $487,000 after purchasing an additional 90,530 shares during the period. Finally, Perceptive Advisors LLC raised its holdings in shares of Veru by 1.4% in the 2nd quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock worth $3,078,000 after purchasing an additional 20,000 shares during the period. 8.83% of the stock is currently owned by hedge funds and other institutional investors.

About Veru

Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Featured Article: S&P 500 Index

Insider Buying and Selling by Quarter for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cloverdale Capital Management LLC Buys 18,772 Shares of Mohawk Industries, Inc.
Cloverdale Capital Management LLC Buys 18,772 Shares of Mohawk Industries, Inc.
Perspecta Inc  Shares Sold by Cloverdale Capital Management LLC
Perspecta Inc Shares Sold by Cloverdale Capital Management LLC
Eminence Capital LP Invests $12.90 Million in Sothebys
Eminence Capital LP Invests $12.90 Million in Sothebys
Eminence Capital LP Has $26.53 Million Stake in Asbury Automotive Group, Inc.
Eminence Capital LP Has $26.53 Million Stake in Asbury Automotive Group, Inc.
Eminence Capital LP Cuts Holdings in TAKE-TWO INTERACTIVE SOFTWARE, INC
Eminence Capital LP Cuts Holdings in TAKE-TWO INTERACTIVE SOFTWARE, INC
Eminence Capital LP Sells 226,265 Shares of Thermo Fisher Scientific Inc.
Eminence Capital LP Sells 226,265 Shares of Thermo Fisher Scientific Inc.


© 2006-2019 Ticker Report